Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. Judge extends block on HHS rule requiring disclosure of financial assistance for dialysis patients
A Texas federal judge today extended a block on a federal rule that would require dialysis providers to disclose any charitable assistance patients receive to insurers.
The indefinite extension was granted by U.S. District Judge Amos Mazzant in Sherman, Texas, in a suit filed by dialysis providers including Fresenius Medical Care, DaVita. Read more
Verb Surgical, Johnson & Johnson‘s joint venture with Google parent Alphabet‘s Verily Life Sciences, said today that it debuted its 1st digital surgery prototype to its collaboration partners at Ethicon Endo-Surgery and J&J.
Robotic surgery, a fast growing field dominated by Intuitive Surgical and its da Vinci system, isn’t using robots yet, according to Verily CEO Andrew Conrad. In a conversation with MassDevice.com last year, Conrad and J&J’s worldwide medical devices chairman Gary Pruden said Verb plans to develop a digital surgery platform to improve surgical outcomes using advanced robotics and informatics. Read more
Medtronic said today the U.S. Centers for Medicare and Medicaid Services released a National Coverage Determination which will cover leadless cardiac pacemakers, including the company’s Micra TPS.
With the designation, Medicare patients will have access to Fridley, Minn.-based Medtronic’s Micra through Medicare’s policy of Coverage with Evidence Development, the company said. Read more
Abiomed posted fiscal 3rd-quarter numbers this morning that beat the consensus estimates on Wall Street, sending share prices up in early trading.
The Danvers, Mass.-based heart pump maker reported profits of $15.4 million, or 34¢ per share, on sales of $114.7 million for the 3 months ended Dec. 31, 2016. That amounts to bottom-line growth of 46.2% on sales growth of 33.7%, compared with Q3 2015. Read more
The FDA recently released a Form 483 it issued to Zimmer Biomet after inspecting its Warsaw, Ind.-based facilities, detailing 14 observations during its inspection.
The 58-page document came after the Agency performed a site inspection at the Zimmer Biomet facility from Sept. 12 to Nov. 22 last year, and included some repeat observations from an earlier 2014 inspection. Read more